ArticlePloS one2025
Interleukin-1β rs16944 and rs1143627 polymorphisms and risk of developing major depressive disorder: A case-control study among Bangladeshi population.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interleukin-1β (C-511T) Genetic Variant and Major Depressive Disorder: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Interleukins in Major Depressive Disorder: Lessons From Autoimmune Diseases and Pathways to Clinical Translation.CNS neuroscience & therapeutics · 2026Review
- The Role of GCH1 Deficiency and Tetrahydrobiopterin in Mental Health.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpidemiological research suggests that altered levels of cytokine are associated with pathophysiology and the development of major depressive disorder (MDD). Based on earlier study, IL-1β rs16944 and rs1143627 polymorphisms may increase the risk of depression. Here, we aimed to evaluate the correlation between these polymorphisms and MDD susceptibility among the population in Bangladesh.
methodsBlood samples were collected from 100 MDD patients and 70 matched controls. Study participants were evaluated by DSM-5 criteria and PCR-RFLP method were applied for genotyping.
resultsThe IL1β rs1143627 and rs16944 polymorphisms were found to have a significant association with the risk of MDD. In case of rs1143627 CT heterozygous genotype (OR = 2.22, 95% CI = 1.08-4.55, p-value = 0.029) and combined CT+TT (OR = 2.35, 95% CI = 1.15-4.79, p-value = 0.019) genotype was strongly associated with the increased risk of MDD in comparison to CC common genotype. Moreover, the over-dominant model indicated a 2.15-fold higher risk for MDD development (OR = 2.15, 95% CI = 1.05-4.40, p-value = 0.036). On the other hand, the IL1β rs16944 polymorphisms revealed that the TC+CC combined genotype in the dominant model showed a 2.06-fold increased risk for MDD development compared to the TT common homozygote (OR = 2.06, 95% CI = 1.06-3.99, p-value = 0.032).
conclusionStudies suggests that IL1β rs16944 and rs1143627 polymorphisms are associated with an increased risk of MDD. These findings will provide us with valuable insights into the pathophysiology of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.